Next Generation Sequencing Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agricul

Next Generation Sequencing Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research, and Others), by End User (Hospital, Research Centers, Pharma and Biotech Firms, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.

NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

Market Dynamics

The increasing adoption of inorganic strategies such as agreements and partnerships among the key players in the market to advance comprehensive genomic profiling using next generation sequencing is expected to drive the market growth over the forecast period. For instance, in January 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a strategic collaboration with Illumina, Inc., a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis, for Illumina to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets. The agreement between Myriad Genetics, Inc., and Illumina, Inc., combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology

Key features of the study:

• This report provides in-depth analysis of the global next generation sequencing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global next generation sequencing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global next generation sequencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial nalysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global next generation sequencing market

Detailed Segmentation:

• Global Next Generation Sequencing, By Technology:
• Whole Genome Sequencing
• Whole Exome Sequencing
• RNA Sequencing
• Targeted Re-sequencing
• Others
• Global Next Generation Sequencing, By Application:
• Drug Discovery
• Personalized Medicine and Genetic Screening
• Disease Diagnosis
• Agriculture and Animal Research
• Others
• Global Next Generation Sequencing, By End User:
• Hospital
• Research Centers
• Pharma and Biotech Firms
• Others
• Global Next Generation Sequencing, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Thermo Fisher Scientific Inc.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Agilent Technologies, Inc
• bioMérieux SA
• Hoffmann-La Roche Ltd
• QIAGEN
• Illumina, Inc.
• Oxford Nanopore Technologies plc.
• BGI
• PerkinElmer Genomics
• Pierian

“*” marked represents similar segmentation in other categories in the respective section.